First non-antipsychotic medication for Alzheimer’s agitation gets FDA approval
FDA Approves First Non-Antipsychotic Treatment for Alzheimer’s Agitation The U.S. Food and Drug Administration has approved a groundbreaking non-antipsychotic medication to treat agitation in individuals with Alzheimer’s disease. Known as Overity, the drug was initially sanctioned by the FDA in 2022 for treating adults suffering from major depressive disorder. Its recent approval expands its use […]